Switch theme
Sign up to access all valuation multiples
Lepu Biopharma Co Ltd is a biopharmaceutical company focusing on oncology therapeutics and has one operating segment. The Group is principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The majority operating entity of the Group is domiciled in the PRC. The company has established an integrated end-to-end platform across drug discovery, clinical development, CMC, and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain.
2018
429
LTM Revenue $54.3M
LTM EBITDA n/a
$969M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lepu Biopharma has a last 12-month revenue of $54.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Lepu Biopharma achieved revenue of $29.0M and an EBITDA of $11.2M.
Lepu Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lepu Biopharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.0M | $29.0M | XXX | XXX | XXX |
| Gross Profit | n/a | $1.7M | XXX | XXX | XXX |
| Gross Margin | NaN% | 6% | XXX | XXX | XXX |
| EBITDA | -$76.7M | $11.2M | XXX | XXX | XXX |
| EBITDA Margin | -3831% | 39% | XXX | XXX | XXX |
| Net Profit | -$130M | -$88.6M | XXX | XXX | XXX |
| Net Margin | -6492% | -306% | XXX | XXX | XXX |
| Net Debt | $17.7M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Lepu Biopharma's stock price is HKD 4 (or $1).
Lepu Biopharma has current market cap of HKD 7.1B (or $917M), and EV of HKD 7.5B (or $969M).
See Lepu Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $969M | $917M | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Lepu Biopharma has market cap of $917M and EV of $969M.
Lepu Biopharma's trades at 19.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Lepu Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lepu Biopharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $969M | XXX | XXX | XXX |
| EV/Revenue | 33.4x | XXX | XXX | XXX |
| EV/EBITDA | 86.6x | XXX | XXX | XXX |
| P/E | -322.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -25.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLepu Biopharma's NTM/LTM revenue growth is -100%
Lepu Biopharma's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Lepu Biopharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lepu Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lepu Biopharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 1347% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -115% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 38% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 203% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 258% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lepu Biopharma acquired XXX companies to date.
Last acquisition by Lepu Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Lepu Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Lepu Biopharma founded? | Lepu Biopharma was founded in 2018. |
| Where is Lepu Biopharma headquartered? | Lepu Biopharma is headquartered in Hong Kong. |
| How many employees does Lepu Biopharma have? | As of today, Lepu Biopharma has 429 employees. |
| Who is the CEO of Lepu Biopharma? | Lepu Biopharma's CEO is Dr. Ziye Sui. |
| Is Lepu Biopharma publicy listed? | Yes, Lepu Biopharma is a public company listed on HKG. |
| What is the stock symbol of Lepu Biopharma? | Lepu Biopharma trades under 02157 ticker. |
| When did Lepu Biopharma go public? | Lepu Biopharma went public in 2022. |
| Who are competitors of Lepu Biopharma? | Similar companies to Lepu Biopharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Lepu Biopharma? | Lepu Biopharma's current market cap is $917M |
| What is the current revenue of Lepu Biopharma? | Lepu Biopharma's last 12-month revenue is $54.3M. |
| What is the current EV/Revenue multiple of Lepu Biopharma? | Current revenue multiple of Lepu Biopharma is 19.1x. |
| What is the current revenue growth of Lepu Biopharma? | Lepu Biopharma revenue growth between 2023 and 2024 was 1347%. |
| Is Lepu Biopharma profitable? | Yes, Lepu Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
